Holen Sie sich die Stockscreener-App
1.86
6.90%
0.12
Handel nachbörslich:
1.76
-0.10
-5.38%
Schlusskurs vom Vortag:
$1.74
Offen:
$1.83
24-Stunden-Volumen:
167.02K
Relative Volume:
0.57
Marktkapitalisierung:
$10.24M
Einnahmen:
$468.00K
Nettoeinkommen (Verlust:
$-10.34M
KGV:
-0.2638
EPS:
-7.05
Netto-Cashflow:
$-8.94M
1W Leistung:
+8.77%
1M Leistung:
-22.18%
6M Leistung:
-31.62%
1J Leistung:
-29.55%
1-Tages-Spanne:
$1.76
$1.89
1-Wochen-Bereich:
$1.68
$1.89
52-Wochen-Spanne:
$1.625
$4.66
Biocardia Inc Stock (BCDA) Company Profile
Firmenname
Biocardia Inc
Sektor
Branche
Telefon
650-226-0123
Adresse
320 SOQUEL WAY, SUNNYVALE, CA
Vergleichen Sie BCDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.90 | 1.23B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.38 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.60 | 112.82M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1534 | 324.91M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.4425 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-16 | Herabstufung | Dawson James | Buy → Neutral |
Biocardia Inc Aktie (BCDA) Neueste Nachrichten
BioCardia, CART-Tech Partner To Develop Heart3D Fusion Imaging For Interventional Cardiology - Nasdaq
Why BioCardia Inc. stock attracts strong analyst attentionCPI Data & Consistent Income Trade Ideas - thegnnews.com
BioCardia Partners with CART-Tech for Heart3D™ Imaging - TipRanks
BioCardia, Inc. (NASDAQ:BCDA) Q2 2025 Earnings Call Transcript - Insider Monkey
BioCardia and CART-Tech Announce Exclusive Partnership to Develo - GuruFocus
BioCardia and CART-Tech Announce Exclusive Partnership to - GlobeNewswire
Revolutionary 3D Heart Imaging System Could Generate $100M Annually, BioCardia-CART-Tech Partnership Reveals - Stock Titan
BioCardia Inc. Breaks Below Key Support LevelOversold Recovery Opportunity Stocks Attract Buyers - 선데이타임즈
Biocardia CEO Peter Altman acquires $1,488 in common stock - MSN
BioCardia (BCDA) Advances with Promising Trial Results and Strat - GuruFocus
BioCardia (BCDA) CEO Altman buys $700 in shares By Investing.com - Investing.com Australia
BioCardia outlines regulatory milestones and targets FDA and PMDA submissions for CardiAMP and Helix in Q4 2025 - MSN
Biocardia 2024 Q2 Earnings Improved Losses Amidst Revenue Decline - AInvest
Real time breakdown of BioCardia Inc. stock performanceFree Fast Gaining Stock Screener Report - Newser
BioCardia sets Q4 2025 for FDA and PMDA submissions for CardiAMP and Helix trials. - AInvest
BioCardia Advances Clinical Trials Amid Financial Challenges - TipRanks
How BioCardia Inc. stock performs during market volatility5-Year Price Trend Summary and Analysis - Newser
BioCardia's (BCDA) Q2 2025 Earnings and Strategic Pivots in Cardiac Regeneration: A Deep Dive into Long-Term Investment Potential - AInvest
BioCardia's 2025 Q2 Earnings Call: Navigating Contradictions in CardiAMP's Regulatory Journey - AInvest
Earnings call transcript: BioCardia Q2 2025 reveals increased R&D expenses By Investing.com - Investing.com Canada
Earnings call transcript: BioCardia Q2 2025 reveals increased R&D expenses - Investing.com
BioCardia Reports Q2 GAAP EPS of -$0.40, Net Cash Used in Operations Increases - AInvest
BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results - The Manila Times
BioCardia Narrows Loss in Fiscal Q2 - The Globe and Mail
BioCardia, Inc. SEC 10-Q Report - TradingView
BioCardia Reports Q2 2025 Business Highlights, Seeks FDA Approval for CardiAMP System - AInvest
BioCardia's CardiAMP Cell Therapy Achieves Key Endpoints in Phase 3 Heart Failure Trial, FDA Meeting Ahead - Stock Titan
Full technical analysis of BioCardia Inc. stockFree Verified Signal From Chart Patterns - Newser
Is BioCardia Inc. meeting your algorithmic filter criteriaPredictive Screener for Daily Trade Watch - Newser
💸 Is there any unusual option activity or capital flow that could affect Blockdag's stock? - AInvest
Can momentum traders help lift BioCardia Inc.Chart Confirmation Setup with ROI Signals - Newser
Should you wait for a breakout in BioCardia Inc.Capital Safe Picks with Consistent Gains - Newser
Is BioCardia Inc. forming a reversal patternFundamental + Technical Combined Watchlist - Newser
Real time social sentiment graph for BioCardia Inc.AI Pattern Recognition and Trade Prediction - Newser
Is BioCardia Inc. still worth holding after the dipEntry Opportunity Screener with Confirmation - Newser
What institutional flow reveals about BioCardia Inc.Free Chart Alert System With Entry Targets - Newser
Can BioCardia Inc. recover in the next quarterMarket Sentiment Tracker with Smart Alerts - Newser
BioCardia Inc.’s volatility index tracking explainedVolume Spike Detection for Early Breakouts - Newser
Using data tools to time your BioCardia Inc. exitMomentum-Based Prediction for Quick Returns - Newser
BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 - The Globe and Mail
Has BioCardia Inc. formed a bullish divergenceFree News Based Entry Opportunity Alerts - Newser
What candlestick patterns are forming on BioCardia Inc.Day Trading Setup Forecast with Trend Model - Newser
Biocardia BCDA 2025Q2 Earnings Preview Upside Ahead on Strategic Product Developments - AInvest
BioCardia to Host Q2 2025 Earnings Call on August 11 - AInvest
BioCardia Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
Earnings Preview: BioCardia to Report Financial Results Post-market on August 11 - 富途牛牛
BioCardia Announces Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 - AInvest
Cellular Therapeutics Pioneer BioCardia Announces Q2 2025 Earnings and Pipeline Update - Stock Titan
TR | OpenAI4o Initiates BioCardia(BCDA.US) With Hold Rating, Announces Target Price $2 - 富途牛牛
What recovery options are there for BioCardia Inc.Weekly High Conviction Trade Setup Analysis - Newser
Finanzdaten der Biocardia Inc-Aktie (BCDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):